ASH 2021 | Long-term follow-up results of TOURMALINE-MM2: IRd vs pbo-Rd in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on the long-term results of the TOURMALINE-MM2 trial comparing ixazomib-lenalidomide-dexamethasone (IRd) to placebo-lenalidomide-dexamethasone (pbo-Rd) in patients with relapsed/refractory (R/R) multiple myeloma (NCT01850524). The results of this study showing a significantly improved progression-free survival (PFS) in patients treated with IRd led to the approval of ixazomib in the relapsed/refractory (R/R) setting. Long-term subgroup analysis revealed that an improved quality of response over time was correlated with better patient outcomes and suggests that treatment with ixazomib should be prolonged over an extended period of time to maximize benefits. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
